Anti-endothelial cell IgE antibodies in children with bronchial asthma
نویسندگان
چکیده
منابع مشابه
Determination the Role of Endothelial Cell-Specific Molecule-1(ESM-1) in Childhood Bronchial Asthma
Background Endothelial Cell-Specific Molecule-1 (ESM-1) is a 50 kDa soluble proteoglycan that is produced mainly the vascular endothelial cells of the kidney and lung. It is produced by the effects of proangiogenic and pro-inflammatory cytokines, and it indicates activation and dysfunction of the vascular endothelium. We aimed to detect the role of ESM-1 in childre...
متن کاملplatelet endothelial cell adhesion molecule-1 polymorphism in patients with bronchial asthma.
asthma is considered as a chronic inflammatory airway disease and defined as increased tracheobronchial responsiveness to variety of stimuli. edema and inflammatory cell infiltration in airway is observed in the asthmatic patients. one of the essential changes in inflammation is adhesion of leukocyte to endothelium and transmigration of leukocytes to the sites of inflammation. unfortunately, li...
متن کاملSpecific IgE, IgG and IgG4 antibodies against house dust mite in patients with bronchial asthma.
Serum levels of total IgE, specific IgE, IgG and IgG4 against house dust mite were measured in mite-sensitive asthma patients receiving immunotherapy with house dust. Serum levels of total IgE, mite specific IgE and IgG did not significantly change during the course of hyposensitization. Increased levels of mite specific IgG4 were observed in patients during immunotherapy. The increase in speci...
متن کاملAnti-IgE: beyond asthma
Omalizumab (anti-IgE ab) is a recombinant humanized monoclonal antibody (rhuMAb-E25) developed by immunizing mice with human IgE. Then, a monoclonal antibody was selected that recognizes IgE at the same site as the highaffinity receptor for IgE (FcεRI). Omalizumab is the only Mab to date that has been found to be effective and approved by both the FDA and European Medicines Agency (EMA) for the...
متن کاملAnti-IgE for chronic asthma in adults and children.
BACKGROUND Omalizumab is a recombinant humanised monoclonal antibody directed against immunoglobulin E (IgE) to inhibit the immune system's response to allergen exposure. Omalizumab is directed against the binding site of IgE for its high affinity Fc receptor. It prevents free serum IgE from attaching to mast cells and other effector cells and prevents IgE mediated inflammatory changes. OBJEC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Allergology International
سال: 2002
ISSN: 1323-8930
DOI: 10.1046/j.1440-1592.2002.00253.x